In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
From a series of pyrrol-containing antibacterial agents, E-3604 was selected for development and compared with nalidixic acid, norfloxacin and ciprofloxacin against strains of clinical isolates. The in vitro activity of E-3604 was greater than that of nalidixic acid, similar to that of norfloxacin and lower than that of ciprofloxacin, except in the case of Staphylococcus where E-3604 showed the best in vitro activity of all the studied compounds, with a MIC range of 0.25-0.03 mg/ml. E-3604, like the other quinolones, presented a pH-dependent variation of activity, greater activity being observed in slightly acidic pH values.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; C053455:E 3604; D009643:Norfloxacin